Clinical Trial Update: A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome [Phase 2]

View source ↗

Summary

Phase II study evaluating venetoclax with dose-adjusted EPOCH-R or R-CHOP for Richter syndrome; current status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Richter Syndrome

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Etoposide (Etoposide)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Venetoclax (venetoclax)
• Vincristine (vincristine)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Richter Syndrome | Phase 2 | Status: ACTIVE_NOT_RECRUITING